Promoter mutant for enhancing clavulanic acid expression
By mutation of the promoter sequence upstream of the clavulanic acid synthesized gene cluster, the problem of insufficient clavulanic acid yield in the prior art was solved, significantly improved yield and enhanced the transcription level of the transcription factor clA, providing industry-based Genetically engineered strains produced.
Patent Information
- Application Number
- CN202411164479.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively increase the yield of clavulanic acid, resulting in limited application efficiency in antibiotic resistance.
Mutations are performed by mutations in the promoter sequence upstream of the pathway-specific transcription factor claR in the clavulanic acid synthesized gene cluster, specifically changing the nucleotide sequence from SEQ ID NO:2 to SEQ ID NO:1, enhancing the expression of the claR gene, This will increase the fermentation yield of clavulanic acid.
The fermentation yield of clavulanic acid is significantly improved, the transcription level of the transcription factor clavulanic acid synthesis pathway is enhanced, and the genetically engineered strains are provided for industrial production.
Smart Images

Figure BDA0005007429480000011 
Figure BDA0005007429480000091 
Figure BDA0005007429480000111
Abstract
Description
Technical Field
[0001] The invention belongs to the field of genetic engineering and relates to a promoter capable of increasing the expression level of a regulatory protein claR and thus enhancing the biosynthesis of clavulanic acid. Background Art
[0002] The long-term and widespread use of β-lactam antibiotics has led to the emergence of a large number of drug-resistant strains. Due to the increasing bacterial resistance, clavulanic acid, as a broad-spectrum β-lactamase inhibitor, has played an important role in addressing bacterial resistance.
[0003] The chemical name of clavulanic acid is (2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, the CAS number is 58001-44-8, and the molecular structure is as follows:
[0004]
[0005] In 1971, Higgens and Kastner first discovered clavulanic acid in Streptomyces clavuligerus (International Journal of Systematic Bacteriology, 1971, 21 (4): 326-330), and in subsequent studies it was confirmed to be an irreversible β-lactamase inhibitor. Since the discovery of clavulanic acid, its huge clinical application value has prompted the development of related industrial strains, the optimization of fermentation processes, and the development of finished drugs. DSM of the Netherlands has taken a number of specific measures to optimize the clavulanic acid fermentation process, which covers a variety of aspects from strain selection, mutagenesis breeding to fermentation process control. DSM uses mutagenesis breeding technology to increase the yield of clavulanic acid. For example, they used nitrosoguanidine as a mutagen to treat Streptomyces clavuligerus for screening. However, after 2006, DSM stopped developing clavulanic acid strains and instead increased production by optimizing the fermentation process, including research on feeding batch fermentation conditions and optimizing fermentation process control, which significantly increased total production.
[0006] Due to the huge commercial value of clavulanic acid, improving the production level of clavulanic acid has important economic significance. For example, we disclosed a method for improving the fermentation level of clavulanic acid-producing bacteria in the patent document with publication number CN118006655A, which improves the fermentation level of clavulanic acid by overexpressing the gene SCLAV_0472 in the clavulanic acid-producing bacteria. Summary of the invention
[0007] During the mutagenesis of clavulanic acid-producing Streptomyces clavuligerus, we screened a mutant strain B021-01 with a large increase in clavulanic acid production. Through comparative genomics studies, it was found that the promoter sequence upstream of the pathway-specific transcription factor claR in the clavulanic acid biosynthesis gene cluster was mutated, and the nucleotide sequence was mutated from SEQ ID NO:2 to SEQ ID NO:1, that is, the base G at position 386 was mutated to A. After further experiments, it was found that the promoter mutant SEQ ID NO:1 can effectively promote the transcription of the transcription factor claR gene, thereby increasing the fermentation yield of clavulanic acid. Accordingly, the present invention includes the following technical solutions:
[0008] The first aspect of the present invention provides a promoter capable of increasing the expression level of a regulatory protein claR (or regulatory factor claR), which is selected from:
[0009] (a) a polynucleotide having a nucleotide sequence of SEQ ID NO: 1;
[0010] (b) a polynucleotide having a nucleotide sequence homology of ≥95%, preferably ≥98%, and more preferably ≥99% to the nucleotide sequence of SEQ ID NO: 1, wherein the polynucleotide has the function of SEQ ID NO: 1 and preferably has an enhanced regulatory effect on claR expression;
[0011] (c) a nucleotide sequence complementary to the nucleotide sequence described in item (a) or (b).
[0012] gatgtacgagcagcggatcagccagatccgcaagctccaggcccaggacatcgcggaggcggtccgctacgccgtgaccgcgccgcaccacgcgaccgtccacgagatcttcatacgccccaccgaccaggtctgacacccgtccgccgaccaggtccacgccgcgcgcccggaccgggtggccggccgtgccgtgccccgtcccccgttcccgggacggcgcccggagcgcgcccgccatccggccgggcgcgttccgcttcccggcgaggagaatccgaagagcggcgctgcctaggatcgattccgaagcaattcaagagccacttcggacaattcagcggtacagtccttgacggaaaagggaaccgacattgtctctcggAtcagaaccgacgtctgctggtgtcagccgatgcgatctgtctttactggacgcg(SEQ IDNO:1).
[0013] gatgtacgagcagcggatcagccagatccgcaagctccaggcccaggacatcgcggaggcggtccgctacgccgtgaccgcgccgcaccacgcgaccgtccacgagatcttcatacgccccaccgaccaggtctgacacccgtccgccgaccaggtccacgccgcgcgcccggaccgggtggccggccgtgccgtgccccgtcccccgttcccgggacggcgcccggagcgcgcccgccatccggccgggcgcgttccgcttcccggcgaggagaatccgaagagcggcgctgcctaggatcgattccgaagcaattcaagagccacttcggacaattcagcggtacagtccttgacggaaaagggaaccgacattgtctctcggGtcagaaccgacgtctgctggtgtcagccgatgcgatctgtctttactggacgcg(SEQ IDNO:2).
[0014] Preferably, the regulatory protein claR is the pathway-specific transcription factor claR in the clavulanic acid biosynthetic gene cluster.
[0015] The second aspect of the present invention provides use of the promoter as described above in improving the fermentation production level / fermentation yield of clavulanic acid-producing bacteria.
[0016] The clavulanic acid-producing bacterium is Streptomyces clavuligerus which contains a clavulanic acid synthesis pathway.
[0017] Preferably, the streptomyces clavuligerus is Streptomyces clavuligerus ATCC 27064 and its derivative strains.
[0018] The third aspect of the present invention provides a claR gene expression cassette, which comprises the above-mentioned promoter and a regulatory protein claR gene located downstream of the promoter, so that the regulatory protein claR gene is placed under the regulation of the promoter.
[0019] Furthermore, the present invention also provides a plasmid comprising the claR gene expression cassette as described above.
[0020] Another aspect of the present invention provides an engineered bacterium of Streptomyces clavuligerus, the genome of which contains the promoter as described above or the claR gene expression cassette as described above.
[0021] Accordingly, the present invention also provides a method for constructing the above-mentioned Streptomyces clavuligerus engineered bacteria, comprising the following steps:
[0022] By gene editing technology, the base in the -10 region of the promoter located upstream of the claR gene in the genome of Streptomyces clavuligerus, i.e., the 55th base upstream of the start codon GTG of the claR gene, is changed from G to A to screen for positive clones; or
[0023] By gene editing technology, the claR gene expression cassette as described above is integrated into the genome of Streptomyces clavuligerus, and positive clones are screened; or
[0024] The plasmid described above was transformed into Streptomyces clavuligerus and positive clones were screened.
[0025] The above-mentioned gene editing technology can be selected from the following groups: homologous double crossover, TALEN system, CRISPR-Cas9 system, CRISPR-Cpf1 system, CRISPR-Cas12 system, CRISPR-BEST system, MuGENT.
[0026] Another aspect of the present invention provides the use of the above-mentioned Streptomyces clavuligerus engineered bacteria in the production of clavulanic acid.
[0027] Specifically, clavulanic acid is produced by fermentation of the above-mentioned Streptomyces clavuligerus engineered bacteria.
[0028] Compared with the initial promoter SEQ ID NO: 2 in Streptomyces clavuligerus ATCC 27064, its mutant SEQ ID NO: 1 can significantly increase the transcription level of the transcription factor claR, strengthen the clavulanic acid synthesis pathway to a certain extent, and thus increase the production of clavulanic acid. The obtained genetically engineered bacteria are expected to be used in industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 It is a bar graph comparing the clavulanic acid production levels of the starting strain Streptomyces clavuligerus ATCC 27064, the mutagenized strain B021-01 and the engineered strain B021-2.
[0030] Figure 2 A comparison chart showing the sequencing results of promoters regulating claR gene expression in the genomes of the starting strain Streptomyces clavuligerus ATCC 27064 and the mutagenized strain B021-01 is shown.
[0031] Figure 3 It is a bar graph comparing the transcription levels of claR gene in the starting strain Streptomyces clavuligerus ATCC 27064 and the engineered strain B021-02. DETAILED DESCRIPTION
[0032] The regulatory protein claR gene is a gene in the clavulanic acid gene cluster, and the claR gene is a gene in the clavulanic acid gene cluster, see the document DOI:10.1007 / s10295-019-02196-0. It is speculated that increasing the expression level of the pathway-specific transcription factor claR in the clavulanic acid synthesis gene cluster to increase the clavulanic acid synthesis gene is an important method to increase the production of clavulanic acid.
[0033] In our strain mutagenesis experiment, we found that after the promoter nucleotide sequence SEQ ID NO: 2 that regulates the expression of the claR gene in the genome of the original clavulanic acid-producing strain Streptomyces clavuligerus ATCC 27064 underwent a forward mutation, the mutant SEQ ID NO: 1 was able to enhance the regulatory effect on claR expression, thereby improving the clavulanic acid fermentation level of the induced strain.
[0034] The promoter SEQ ID NO: 2 is referred to herein as the initial promoter or original promoter, which is relative to the mutant promoter SEQ ID NO: 1. For the sake of convenience, the initial promoter SEQ ID NO: 2 and its mutants such as SEQ ID NO: 1 can be collectively referred to as "promoters" herein. The difference between the initial promoter SEQ ID NO: 2 and the promoter mutant SEQ ID NO: 1 is that the 386th base in the promoter sequence SEQ ID NO: 2, 55 positions upstream of the start codon GTG of the claR gene, is changed from G to A.
[0035] Of course, the present invention does not exclude the possibility that base mutations at other positions in SEQ ID NO: 2 can also produce positive mutations that enhance the expression level of clavulanic acid, which needs further research and attempts.
[0036] As used herein, the terms "(clavulanic acid fermentation level) increase", "elevate" or "increase" may mean an increase of at least 10% compared to a reference level (such as a starting strain), for example, an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or up to and including a 100% increase, or any increase between 10%-100%, or an increase of at least about 2 times, or at least about 3 times, or at least about 4 times, or at least about 5 times, or at least about 10 times compared to a reference level.
[0037] In this article, for the sake of simplicity of description, a certain protein, such as the regulatory protein claR, is sometimes used interchangeably with the name of its coding gene (DNA), and those skilled in the art should understand that they represent different types of substances in different description occasions. Those skilled in the art can easily understand their meanings based on the context and context. For example, for claR, when used to describe the function or category of a specific transcription factor, it refers to the protein; when described as a gene, it refers to the coding gene of the protein.
[0038] Since the claR gene is relatively fixed, the claR gene expression cassette comprising a promoter mutant and a claR gene located downstream and regulated thereby can be easily constructed. These genes, expression cassettes, plasmids, and transformants can be obtained by genetic engineering construction methods well known to those skilled in the art.
[0039] The claR gene expression cassette of the present invention can usually be obtained by PCR amplification, recombination or artificial synthesis. For PCR amplification, conventional techniques can be used to obtain Streptomyces clavuligerus genomic DNA, and then primers are designed based on the nucleotide sequence disclosed in the present invention, especially the open reading frame sequence, to amplify the claR gene expression cassette from the genomic DNA.
[0040] As used herein, the "expression cassette", "gene expression cassette" or "nucleic acid construct" refers to a gene expression system that contains all the necessary elements required to express the target polypeptide claR, which generally includes the following elements: promoter SEQ ID NO: 1, a gene sequence encoding the polypeptide claR, and a terminator; in addition, it may optionally include a signal peptide coding sequence, etc.; these elements are operably linked.
[0041] As used herein, the "expression construct" or "expression construct" refers to a recombinant DNA molecule, which comprises the expected nucleic acid SEQ ID NO: 1 and a claR coding sequence, which may comprise one or more claR gene expression cassettes. The "construct" is usually contained in an expression vector (plasmid vector).
[0042] As used herein, the term "operably linked (connected)" or "operably linked (connected)" refers to the functional spatial arrangement of two or more nucleic acid regions or nucleic acid sequences. For example, the promoter region SEQ ID NO: 1 is placed at a specific position relative to the target claR gene nucleic acid sequence, so that the transcription of the claR gene nucleic acid sequence is guided by the promoter region SEQ ID NO: 1, and thus the promoter region SEQ ID NO: 1 is "operably linked" to the claR gene nucleic acid sequence.
[0043] The nucleic acid construct of the present invention can be manipulated in a variety of ways to ensure the expression of the protein claR. The nucleic acid construct can be manipulated according to the different expression vectors or requirements before inserting the nucleic acid construct into the vector. The technology of using recombinant DNA methods to change polynucleotide sequences is known in the art.
[0044] In certain embodiments, the nucleic acid construct is a vector. The vector may be a cloning vector, an expression vector, or a gene knock-in vector. The claR gene expression cassette of the present invention may be cloned into many types of vectors, for example, plasmids, phagemids, phage derivatives, animal viruses, and cosmids. The cloning vector may be used to provide the claR gene expression cassette of the present invention. The expression vector may be provided to the cell in the form of a bacterial vector or a viral vector. The expression of the claR gene is usually achieved by operably connecting the claR gene to the promoter SEQ ID NO: 1 downstream and incorporating the construct into the expression vector. The vector may be suitable for replication and integration of eukaryotic cells.
[0045] A knock-in vector can be used to integrate the polynucleotide sequence SEQ ID NO:1 described herein into the region of interest of the host genome, i.e., the claR gene coding region. Typically, the knock-in vector may contain, in addition to the polynucleotide sequence, a 5' homology arm and a 3' homology arm required for homologous recombination of the genome. In some embodiments, the nucleic acid construct herein contains a 5' homology arm, a polynucleotide sequence described herein, and a 3' homology arm. When using a knock-in vector, the CRISPR / Cas9 technology can be used simultaneously to homologously recombine the polynucleotide sequence to the position of interest. The CRISPR / Cas9 technology guides the Cas9 nuclease to modify the genome at the insertion position by designing a guide RNA for the target gene, thereby increasing the homologous recombination efficiency of the gene modification region, and homologously recombine the target fragment claR gene expression cassette or promoter SEQ ID NO:1 contained in the knock-in vector to the target site. The steps of the CRISPR / Cas9 technology and the reagents used, such as Cas9 nuclease, are well known in the art.
[0046] Methods well known to those skilled in the art can be used to construct nucleic acid constructs. These methods include in vitro recombinant DNA techniques, DNA synthesis techniques, in vivo recombination techniques, etc.
[0047] The present invention is further described in detail below in conjunction with specific examples. It should be understood that the following examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0048] Example
[0049] This article involves the addition amount, content and concentration of various substances, and the percentages mentioned here refer to the mass percentages unless otherwise specified.
[0050] Materials and methods:
[0051] The gene sequencing, primers and gene synthesis in the examples were all commissioned to Suzhou Genewise Biotechnology Co., Ltd.
[0052] BLZ medium: 24g / L soybean superfine powder, 10g / L corn starch, 5g / L yeast autolysate, 0.8g / L potassium dihydrogen phosphate, adjust pH to 6.9-7.1. Dispense into 500mL shake flasks, 50mL of liquid per bottle, add 0.5mL of triglyceride to each bottle, sterilize at 121℃ for 20min, and use for shake flask seed culture.
[0053] BLF medium: 30g / L soybean superfine powder, 16g / L corn starch, 14g / L soybean protein extract, 1.95g / L potassium hydrogen phosphate, 1.5g / L potassium chloride, 1.0g / L magnesium chloride hexahydrate, 0.38g / L calcium chloride dihydrate, 0.18g / L sodium chloride, 0.08g / L ferric chloride hexahydrate, 0.02g / L copper chloride, 0.01g / L zinc chloride, 200mL / L MOPS solution, adjust the pH to 6.9-7.1. Dispense into 250mL shake flasks, each bottle has 50mL of liquid, add 1mL of triglyceride to each bottle, sterilize at 121℃ for 20min, and use for shake flask fermentation culture. MOPS solution: 34g MOPS is added to 50mL of purified water, and then 88.5mL of 1M sodium hydroxide solution is added to 200mL, and the pH is adjusted to 7.1-7.3.
[0054] The plasmid pJTU1278 involved in the embodiment has been recorded in the SCI database document Xinjuan Ning, Xinran Wang, Yuanting Wu, Qianjin Kang* and Linquan Bai*: Identification and Engineering of Post-PKS Modification Bottlenecks for Ansamitocin P-3 Titer Improvement in Actinosynnema pretiosum subsp. pretiosum ATCC 31280. Biotechnology Journal 2017, 12, 1700484.
[0055] HPLC detection conditions of clavulanic acid: Agilent 1260 liquid chromatograph, chromatographic column C18 (4.6×250 mm, 5 μm), mobile phase: mobile phase A (10 mmol tetrabutylammonium hydrogen sulfate, 11.5% acetonitrile, pH=6.0): mobile phase C (acetonitrile) = 90:10 (V / V), detection wavelength: 210 nm, column temperature: 33° C., flow rate: 1 ml / min, injection volume: 20 μl.
[0056] Example 1: Mutagenesis of clavulanic acid producing strain Streptomyces clavuligerus ATCC 27064
[0057] When the industrial strain Streptomyces clavuligerus ATCC 27064 was mutagenized, a mutant strain B021-01 with significantly improved clavulanic acid fermentation level was obtained. The specific process includes the following steps.
[0058] 1. Preparation of spore suspension: Add 5 ml of sterile water to the culture plate of the starting strain Streptomyces clavuligerus ATCC 27064, gently scrape the bacteria with a sterile toothpick, mix them by blowing and beating with a 1 ml pipette for 5 times, put them into a 100 ml sterile conical flask (containing 2 g of glass beads), seal the flask with a sealing film, put it into a constant temperature shaker at 200 rpm, shake and break up the bacteria, use a 1 ml pipette to draw up the bacterial solution, filter it into a new sterile conical flask with a sterile funnel with 0.45 μm filter paper, draw up the filtrate and put it into a sterile 2 ml EP tube (2 tubes), centrifuge at 3000 g / min for 10 min, draw up the supernatant with a pipette and discard it, and collect the spore suspension.
[0059] 2. NTG mutagenesis: After collecting spores from the spore suspension, add 1 mL of TM buffer (Tris-maleic acid buffer, 0.05 mM pH 8.5) to each tube, mix well with a 1 mL pipette for 5 times, take one tube and add it to the EP tube with 0.1 mg of nitrosoguanidine (NTG), and the other tube as a control without NTG. After wrapping the EP tube with NTG with tin foil, put the two EP tubes into a 30°C, 200 rpm shaker for 30 minutes, and add sodium thiosulfate buffer to terminate. Then centrifuge the sample at 3000 g / min for 10 minutes, remove the supernatant with a pipette, add an equal volume of buffer and repeat twice, add water to resuspend the precipitate, dilute the induced spores according to the gradient, take 100 μL and spread on the MS plate, invert the spread plate and place it in a 28°C incubator for 7 days, and select the colonies with vigorous growth.
[0060] 3. Preliminary screening: Use a spray gun to add 800 μL of seed culture medium (24 g / L soybean cake powder, 10 g / L soluble starch, 5 g / L yeast autolysate, 0.8 g / L potassium dihydrogen phosphate, adjust the pH to 6.9-7.1) to each well of a 48-well plate. Use a sterile toothpick to pick up half of the single colonies grown and put them into the seed culture medium for stirring and mixing. The 48-well plate was placed in a constant temperature shaker, cultured at 220-250 rpm and 30°C for 24 h, and then transferred to a new sterile 48-well plate with an inoculum of 10 v / v%, each well containing 800 μL of fermentation medium (28 g / L soybean cake extract, 12 g / L starch, 8 g / L soybean protein extract, 1.45 g / L dipotassium hydrogen phosphate, 1.9 g / L potassium chloride, 1.0 g / L magnesium chloride hexahydrate, 0.7 g / L calcium chloride dihydrate, 0.18 g / L sodium chloride, 0.08 g / L ferric chloride hexahydrate, 0.02 g / L copper chloride, 0.01 g / L zinc chloride, 120 mL / L 17% MOPS solution, pH adjusted to 6.9-7.1.), and continued to be placed in a constant temperature shaker, cultured at 220 rpm and 26°C for 28 h. After the culture was completed, the 48-well plate was removed from the shaker, centrifuged at 4000 rpm for 2 min, and samples were taken for HPLC detection.
[0061] 4. Shake flask rescreening: The mutant strains with improved yield obtained in the initial screening were spread on solid MS medium for activation. After culturing at 30°C for 10 days, spores were scraped from a plate and inoculated into BLZ medium. The culture was carried out at 26°C and 200-220rpm for 48h. The inoculation amount was transferred to BLF medium at 5%, and fermented at 25°C and 220-260rpm for 120h. The fermentation liquid was collected for clavulanic acid detection. A mutant strain was screened, and the measured clavulanic acid yield was 176% higher than that of the starting strain. Figure 1 As shown, the mutant strain was named B021-01.
[0062] Example 2: Genome analysis of mutant strain B021-01
[0063] The genomes of the mutagenic strain B021-01 and the starting strain ATCC 27064 were sequenced and compared to investigate whether gene mutations occurred. The steps are as follows.
[0064] The obtained mutagenic strain B021-01 and the starting strain Streptomyces clavuligerus ATCC 27064 were cultured on MS plates at 30°C for 5-7 days. After the culture was completed, spores from one plate were scraped and inoculated into the seed liquid culture medium. The mycelium was collected after 24 hours of culture. The two strains were sent to Suzhou Jinweizhi Biotechnology Co., Ltd. for gene resequencing. The SNP results showed that the promoters upstream of the claR gene in the genomes of the two strains were slightly different, and a point mutation occurred. The nucleotide sequence was mutated from SEQ ID NO:2 to SEQ ID NO:1, that is, the 55th base G upstream of the start codon GTG of the claR gene was mutated to A.
[0065] The promoter of the claR gene was obtained by PCR amplification using the mycelial DNA of the strains Streptomyces clavuligerus ATCC 27064 and B021-01 as templates and primers claRp-F / R. The obtained PCR fragment was sequenced, and the results showed that the base at position 55 (i.e., position 386 of SEQ ID NO: 2) in the region upstream of the claR gene promoter was indeed changed from G to A, as shown in FIG. Figure 2 shown.
[0066] The PCR primer sequences are:
[0067] claRp-F:accaggtctgacacccgtccgccga;
[0068] claRp-R: gggccgtgtggcggctgcgca.
[0069] PCR reaction system: DNA template 30ng, primer 20pmol, DMSO 2μL, PrimerSTAR Max DNA Polymerase 25μL, add pure water to make up to 50μL;
[0070] PCR conditions: 95°C for 10 min; 95°C for 30 s; 60°C for 30 s; 72°C for 15 s, 30 cycles; 72°C for 10 min.
[0071] This result indicates that the increase in clavulanic acid production in the fermentation broth of mutant strain B021-01 may be due to the increase in claR transcription level, which leads to a significant increase in the corresponding yield, because claR, as a pathway-specific transcription factor, can positively regulate the transcription levels of multiple clavulanic acid biosynthesis genes, as reported in the literature (Cho HS, Jo JC, Shin CH, et al. Improved production of clavulanic acid by reverse engineering and overexpression of the regulatory genes in an industrial Streptomyces clavuligerus strain. J Ind Microbiol Biotechnol, 2019, 46 (8): 1205-1215. DOI: 10.1007 / s10295-019-02196-0.) and the increase in claR transcription level may be closely related to the promoter mutation.
[0072] Example 3: Verification of the efficacy of mutant promoters
[0073] The regulatory effect of the promoter mutant was verified by constructing an engineered bacterium in which the promoter mutant drives the expression of claR, and the steps are as follows.
[0074] 1. Construction of engineered bacteria:
[0075] Using Streptomyces clavuligerus genomic DNA as a template, using primers pB021-1F / R, fragment UHA was obtained by PCR amplification. Using primers pB021-2F / R, fragment DHA was obtained by PCR amplification. Fragments UHA and DHA were cloned at the XbaI / EcoRI sites in plasmid pJTU1278 by a one-step assembly method to obtain plasmid pB021-01.
[0076] Using pB021-01 as a template, PCR was used to amplify the skeleton containing fragments UHA and DHA. Using B021-1 mycelium as a template, the mutant claR promoter was amplified. The mutant promoter sequence was cloned between fragments UHA and DHA by one-step cloning to obtain plasmid pB021-02.
[0077] *The primer sequences used in the first step are:
[0078]
[0079] PCR system and conditions used for gene fragment preparation:
[0080] PCR reaction system: DNA template 30ng, primer 20pmol, 50% DMSO 4μL, PrimerSTAR max, add pure water to make up to 50μL;
[0081] PCR conditions: 95°C for 5 min; 95°C for 15 s; 60°C for 15 s; 72°C for 30 s; 30 cycles; 72°C for 10 min.
[0082] *Assembly system and conditions in the first step: pJTU1278 (linearized) 0.03 pmol, fragment 1 0.03 pmol; fragment 2 0.03 pmol; 2×Hieff Enzyme Premix 10 μL, add water to 20 μL, react at 50℃ for 30 min to transform DH5a.
[0083] The plasmid vector pB021-01 for knocking out the claR promoter obtained in the first step was introduced into the recipient bacteria Streptomyces clavuligerus ATCC 27064 through conjugation transfer for homologous exchange, and the correct conjugants were screened through resistance screening for single exchange, relaxed culture and PCR verification, and the claR promoter-deficient strain was screened. Based on this, pB021-02 was conjugated and transferred, and the correct double-exchange strain was screened to obtain the promoter after the mutation was inserted upstream of the claR gene, that is, the mutant strain B021-02 in which the 55th base upstream of claR was changed from G to A. Specifically, the following steps are included:
[0084] Plasmid pB021-01 was transformed into host ET12567 (pUZ8002). The corresponding ET12567 (pUZ8002) was inoculated into LB medium containing three antibiotics: ampicillin (final concentration 100 μg / mL), kanamycin (final concentration 50 μg / mL) and chloramphenicol (final concentration 25 μg / mL), cultured at 37°C for 20 hours, and then rinsed with fresh LB solution to remove the antibiotics in the culture. Fresh rod-shaped Streptomyces spores were collected from the plate and centrifuged at 4000 rpm for 5 minutes, the supernatant was discarded, and the spores were resuspended with 5 mL TES (0.05 M, pH 8.0) solution. The centrifuge tube was placed in a 50°C water bath for 10 minutes, and then cooled to room temperature with running tap water. 5 mL 2× spore pre-germination medium was added to the tube, and then incubated at 37°C and 200 rpm for 3 hours. After the incubation is completed, centrifuge at 4000rpm for 10min, discard the supernatant, and rinse the spores with fresh LB solution. Then mix it with the previously prepared host bacteria ET12567 (pUZ8002) (the ratio of the recipient bacteria cells to the donor bacteria is about 1:10) and evenly spread it on the MS solid medium containing 10mM magnesium ions and culture it in a 37℃ incubator. After 20h, take out the plate, add thiostrepton (final concentration 25μg / mL) and nalidixic acid (final concentration 40μg / mL) two antibiotics to 1mL sterile water, mix them and cover them on the MS solid medium, dry the solid medium and transfer it to a 30℃ incubator for inverted culture. Generally, after 3 to 5 days, conjugates can be seen growing on the plate. They are transferred to MS solid medium containing thiostrepton (final concentration 25μg / mL) and nalidixic acid (final concentration 40μg / mL) to expand the culture, and single exchange mutants are screened by mycelial PCR and sequencing verification. Pick 3 to 6 correct single exchange bacteria, take 200 μL of mycelium from each single colony and spread it on MS plates without resistance, culture at 30°C until sufficient spores are produced, collect spores and dilute them to a concentration range of 10 -6 ~10 -10 The double-exchange strain was then inoculated onto an MS plate and grown for 2 to 3 days to obtain a single colony. PCR and sequencing were used to verify the double-exchange strain.
[0085] Starting from the claR promoter deletion strain, the above method was used to further transfer the strain into pB021-02, and after single exchange, screening, relaxation, etc., the strain B021-2 with the inserted mutant promoter SEQ ID NO: 1 was screened out.
[0086] The above culture medium includes:
[0087] LB medium: 10 g / L tryptone, 5 g / L yeast extract, 10 g / L sodium chloride, pH 7.2 (LB solid medium plus 20 g / L agar powder).
[0088] 2× spore pre-germination medium: yeast extract 10 g / L, casamino acid 10 g / L, calcium chloride 0.01 M, sterilized at 121°C for 20 min, used for spore germination culture of Streptomyces in conjugation transfer experiments.
[0089] TES (0.05M, pH 8.0) solution: 1.15 g N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid was diluted to 100 mL pure water and the pH was adjusted to 8.0. Sterilize at 121°C for 20 min and set aside. Used for conjugation transfer spore germination of Streptomyces.
[0090] 2. Extraction of total RNA:
[0091] The original strain Streptomyces clavuligerus ATCC 27064 and the engineered strain B021-02 were cultured on MS plates at 30°C for 5-7 days. After the culture was completed, spores from one plate were scraped and inoculated into BLZ seed medium, and cultured at 26°C and 200rpm / min for 48h. The inoculation amount was transferred to BLF fermentation medium at 5v / v%, and fermented at 25°C and 200rpm / min. After fermentation for 72h, 500μL of the fermentation broth of the two strains were taken, centrifuged at 4°C and 12000rpm for 5min, the mycelium was collected, the supernatant was discarded, and the mycelium was washed with sterile water until no fermentation broth remained. 1mL Redzol solution and an appropriate amount of glass beads with a diameter of 1μm were added, and the mycelium was broken with a cell disruptor (24, Bertin Technologies) under the conditions of 70Hz, 30s, 2 cycles, and a break of 20s. Add 200μL of pH 8.0 phenol chloroform and shake to mix, centrifuge at 4℃, 13300rpm for 10min. Take the supernatant to a new EP tube (the EP tubes and gun tips used in the RNA extraction process are all special RNA-free products, and ordinary sterilized products cannot be used), add 200μL of chloroform and shake to mix, centrifuge at 4℃, 13300rpm for 10min. If there are many proteins in the middle interface, repeat this step. Transfer the supernatant to a new EP tube, add 200μL of anhydrous ethanol, mix well, add to the centrifuge column, and put it into the collection tube. After standing at room temperature for 2min, centrifuge at 6000rpm for 1min, and discard the waste liquid in the collection tube. Add 600μL Washingbuffer to wash twice, discard the waste liquid in the collection tube, and centrifuge at 6000rpm for 2min. Put the centrifuge column into a new EP tube, add 50μL of DEPC-treated water to the center of the centrifuge column, and centrifuge at 12000rpm for 1min. The RNA solution obtained by centrifugation was added to the center of the centrifugal column and centrifuged at 12000rpm for 1min to increase the RNA yield. 1μL RNA solution was taken and the concentration of the RNA solution was detected by Nanodrop (Thermo), and the A260 / A280 value was recorded. If the value was between 1.8-2.0, the RNA quality was considered qualified and could be stored at -80℃ for subsequent experiments.
[0092] 3. Removal of DNA from RNA samples and reverse transcription
[0093] Since the extraction of total RNA may be contaminated by genomic DNA, the genomic DNA in the RNA must be removed. The DNA digestion system is as follows:
[0094]
[0095] Place the above 50μL system in a 37℃ water bath for 4h. Place on ice immediately after the reaction is completed. Add 5μL 50mM EDTA to each system and place in a 65℃ water bath for 10min to inactivate DNase I, terminate digestion, and protect RNA. Place on ice immediately after the water bath is completed. Take 1μL of digested RNA solution and use conventional PCR to test whether the DNA is completely digested. For qualified RNA, PCR cannot amplify bands. At the same time, take 1μL of digested RNA solution and use Nanodrop (Thermo) to detect the concentration of the RNA solution, and record the A260 / A280 value. If the value is between 1.8-2.0, the RNA quality is considered qualified and can be stored at -80℃ for subsequent experiments.
[0096] The reverse transcription PCR system for Streptomyces RNA is as follows:
[0097]
[0098] 12.5 μL of the system was mixed and placed in a 65°C water bath for 5 min. After the reaction was completed, it was immediately placed on ice and 7.5 μL of the following system was added and mixed.
[0099]
[0100] Place the above 20 μL system into a PCR instrument, and the PCR program is: 25°C for 5 min, 42°C for 60 min, and 72°C for 5 min. The cDNA obtained after reverse transcription can be stored at -80°C for a long time.
[0101] 4. Fluorescence quantitative PCR
[0102] Fluorescence quantitative PCR uses ABI's 7500Fast fluorescence quantitative PCR instrument and Fermentas' MaximaTM TBGreen kit. 20 μL of the system obtained by reverse transcription is diluted with 80 μL of water to obtain a DNA template. The fluorescence quantitative PCR system is as follows:
[0103]
[0104]
[0105] Add the above 20 μL system into a 96-well plate and place it into a fluorescent quantitative PCR instrument. The PCR program is: Stage 1: pre-denaturation, Reps: 1, 95℃30sec; Stage 2: PCR reaction, Reps: 40, 95℃5sec, 60℃30sec; Stage 3: Melting curve ramping from 65℃to 95℃(increment 0.5℃ / 5s).
[0106] The primers used for quantitative PCR are as follows:
[0107]
[0108] hrdB was selected as the internal reference gene, and the transcription levels of other related genes were measured using 2 -△△Ct The results of fluorescence quantitative PCR are shown in Figure 3 As shown, at 72h of fermentation, the transcription level of the claR gene of the engineered Streptomyces clavuligerus B021-2 increased by 326% compared with the starting strain, proving that the promoter mutant SEQ ID NO: 1 can significantly increase the transcription level of the claR gene in Streptomyces clavuligerus.
[0109] 5. Investigate the effects of other mutations of the 386th base G of the promoter SEQ ID NO: 2
[0110] According to the method of step 1, based on the deletion of the claR promoter sequence, the promoter SEQ ID NO:2 inserted upstream of the claR gene was subjected to G→C mutation and G→T mutation, respectively, to obtain the engineered bacteria B021-02-2 (i.e., G→C) and B021-02-3 (i.e., G→T). According to the methods of steps 2 to 4, the transcription level of the claR gene caused by these three mutations was investigated. The experiment found that the transcription levels of the claR gene of the engineered bacteria B021-02-2 and B021-02-3 were 89% and 117% respectively compared with the original strain Streptomyces clavuligerus ATCC 27064, indicating that the transcription level of the claR of the two engineered bacteria was not improved, suggesting that the G→A mutation of the 386th base of the initial promoter SEQ ID NO:2 was a forward mutation, and the promoter mutant SEQ ID NO:1 could significantly increase the transcription of claR, and finally significantly increase the clavulanic acid production of the strain.
[0111] Although the above embodiment only uses Streptomyces clavuligerus ATCC 27064 and its mutagenic derivative strain B021-1 as an example to verify the function of the promoter mutant SEQ ID NO: 1, those skilled in the art should understand that without violating the concept of the present invention, those skilled in the art can make various changes or modifications on this basis, such as applying to other clavulose Streptomyces such as the improvement of Streptomyces clavuligerus ATCC 27064 derivative strains, and the equivalent forms of various deformations or modifications made thereby should also fall within the scope of the present invention.
Claims
1. A promoter for increasing the expression level of a regulatory protein claR, characterized in that: It is selected from: (a) a polynucleotide having a nucleotide sequence of SEQ ID NO: 1; (b) a polynucleotide having a nucleotide sequence with a homology of ≥ 95% with the nucleotide sequence shown in SEQ ID NO: 1, wherein the polynucleotide has the function of SEQ ID NO: 1; (c) a nucleotide sequence complementary to the nucleotide sequence described in item (a) or (b).
2. The promoter according to claim 1, characterized in that The regulatory protein claR is a pathway-specific transcription factor claR in the clavulanic acid synthesis gene cluster.
3. Use of the promoter as claimed in claim 1 in improving the fermentation production level of clavulanic acid producing bacteria.
4. The use according to claim 3, characterized in that The clavulanic acid producing bacterium is Streptomyces clavuligerus which contains a clavulanic acid synthesis pathway.
5. The use according to claim 3, characterized in that The clavulform streptomyces is streptomyces clavulformis ATCC 27064 and its derivative strains.
6. A claR gene expression cassette, characterized in that: It comprises the promoter as claimed in claim 1 and a regulatory protein claR gene located downstream thereof.
7. A plasmid, characterized in that Comprising the claR gene expression cassette as claimed in claim 6.
8. An engineered strain of Streptomyces clavuligerus, characterized in that: Its genome comprises the promoter according to claim 1 or the claR gene expression cassette according to claim 6.
9. A method for constructing the engineered bacterium of Streptomyces clavuligerus as claimed in claim 8, characterized in that: The steps include: By gene editing technology, the base in the -10 region of the promoter located upstream of the claR gene in the genome of Streptomyces clavuligerus, i.e., the 55th base upstream of the start codon GTG of the claR gene, is changed from G to A to screen for positive clones; or Integrating the claR gene expression cassette as claimed in claim 6 into the genome of Streptomyces clavuligerus by gene editing technology, and screening positive clones; or The plasmid as claimed in claim 7 is transformed into Streptomyces clavuligerus, and positive clones are screened.
10. Use of the engineered strain of Streptomyces clavuligerus according to claim 8 in producing clavulanic acid.
Citation Information
Cited By
New method for improving fermentation yield of clavulanic acid
CN121472284A
